Randomised, placebo-controlled, double-blind, parallele-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

Carlo Antonio Barone

Research output: Contribution to journalArticlepeer-review

128 Citations (Scopus)

Abstract

Abstract Background: This phase III study investigated the addition of aflibercept to gemcitabine, in patients with advanced pancreatic cancer. Patients and methods: Patients with metastatic pancreatic cancer were randomly assigned to receive either intravenous (i.v.) aflibercept, 4 mg/kg every 2 weeks, or matching placebo combined with gemcitabine, 1000 mg/m2 i.v. weekly for 7 weeks out of 8, then weekly for 3 weeks out of 4 until progressive disease, unacceptable toxicity or withdrawal of consent. The primary objective was to demonstrate an improvement in overall survival (OS) between the treatment arms. Results: The study was stopped for futility following a planned interim analysis of OS in 427 randomised patients. With a median follow-up of 7.9 months, based on the 546 patients at study termination, median OS was 7.8 months in the gemcitabine plus placebo arm (n = 275) versus 6.5 months in the gemcitabine plus aflibercept arm (n = 271), which was not significant (hazard ratio 1.165, 95% confidence interval (CI) 0.921–1.473, p = 0.2034). Median progression-free survival was 3.7 months in both arms. Treatment discontinuations due to adverse events were more frequent in the aflibercept than in the placebo-containing arm (23% versus 12%). Conclusion: Adding aflibercept to gemcitabine did not improve OS in patients with metastatic pancreatic cancer.
Original languageEnglish
Pages (from-to)2633-2642
Number of pages10
JournalEuropean journal of cancer
Volume49
DOIs
Publication statusPublished - 2013

Keywords

  • Aflibercept
  • Angiogenesis

Fingerprint

Dive into the research topics of 'Randomised, placebo-controlled, double-blind, parallele-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer'. Together they form a unique fingerprint.

Cite this